According to the authorities, the patient had initially complained of weakness on February 24 and sought treatment at a ...

Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside ...

Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments. Potential regulatory concerns may arise if the FDA ...

A 50-year-old man from Nira near Pune died while undergoing treatment for suspected Guillain-Barré Syndrome (GBS) after ...

LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III, ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...

Guillain-Barre syndrome (GBS) is an inflammatory disease that affects the nerves. It is thought to be an autoimmune disorder, and while the cause is not fully understood, it often arises after a ...

Patients with Guillain- Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness.